{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:28:51Z","timestamp":1794410931703,"version":"4.9.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atypical antipsychotics (AAPs) are considered to possess superior efficacy for treating both the positive and negative symptoms of schizophrenia; however, AAP use often causes excessive weight gain and metabolic abnormalities. Recently, several reports have demonstrated that AAPs activate sterol regulatory element-binding protein (SREBP). SREBP, SREBP cleavage-activating protein (SCAP) and insulin-induced gene (Insig) regulate downstream cholesterol and fatty acid biosynthesis. In this study, we explored the effects of clozapine, olanzapine and risperidone on SREBP signaling and downstream lipid biosynthesis genes in the early events of adipogenic differentiation in adipose-derived stem cells (ASCs). After the induction of adipogenic differentiation for 2 days, all AAPs, notably clozapine treatment for 3 and 7 days, enhanced the expression of SREBP-1 and its downstream lipid biosynthesis genes without dexamethasone and insulin supplementation. Simultaneously, protein level of SREBP-1 was significantly enhanced via inhibition of Insig-2 expression. By contrast, SREBP-1 activation was suppressed when Insig-2 expression was upregulated by transfection with Insig-2 plasmid DNA. In summary, our results indicate that AAP treatment, notably clozapine treatment, induces early-stage lipid biosynthesis in ASCs. Such abnormal lipogenesis can be reversed when Insig-2 expression was increased, suggesting that Insig\/SCAP\/SREBP signaling may be a therapeutic target for AAP-induced weight gain and metabolic abnormalities.<\/jats:p>","DOI":"10.1038\/s41598-017-11323-9","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T14:11:28Z","timestamp":1504275088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells"],"prefix":"10.1038","volume":"7","author":[{"given":"Chien-Chih","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Tzu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3701-3449","authenticated-orcid":false,"given":"Toshiaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"key":"11323_CR1","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1592\/phco.24.17.1759.52346","volume":"24","author":"MW Jann","year":"2004","unstructured":"Jann, M. W. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy \n                           24, 1759\u20131783, doi:10.1592\/phco.24.17.1759.52346 (2004).","journal-title":"Pharmacotherapy"},{"key":"11323_CR2","unstructured":"Bridler, R. & Umbricht, D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med Wkly \n                           133, 63\u201376, doi:2003\/05\/smw-10003 (2003)."},{"key":"11323_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/WNF.0b013e31824d5288","volume":"35","author":"R Bou Khalil","year":"2012","unstructured":"Bou Khalil, R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol \n                           35, 141\u2013147, doi:10.1097\/WNF.0b013e31824d5288 (2012).","journal-title":"Clin Neuropharmacol"},{"key":"11323_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.9758\/cpn.2013.11.2.80","volume":"11","author":"YK Ko","year":"2013","unstructured":"Ko, Y. K., Soh, M. A., Kang, S. H. & Lee, J. I. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clin Psychopharmacol Neurosci \n                           11, 80\u201388, doi:10.9758\/cpn.2013.11.2.80 (2013).","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"11323_CR5","first-page":"801","volume":"53","author":"MA Said","year":"2012","unstructured":"Said, M. A. et al. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia. Singapore Med J \n                           53, 801\u2013807 (2012).","journal-title":"Singapore Med J"},{"key":"11323_CR6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2298\/SARH1512712P","volume":"143","author":"I Popovic","year":"2015","unstructured":"Popovic, I. et al. Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome. Srp Arh Celok Lek \n                           143, 712\u2013718 (2015).","journal-title":"Srp Arh Celok Lek"},{"key":"11323_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2015.00297","volume":"9","author":"A Ventriglio","year":"2015","unstructured":"Ventriglio, A., Gentile, A., Stella, E. & Bellomo, A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci \n                           9, 297, doi:10.3389\/fnins.2015.00297 (2015).","journal-title":"Front Neurosci"},{"key":"11323_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/pds.3912","volume":"25","author":"HJ Luijendijk","year":"2016","unstructured":"Luijendijk, H. J., de Bruin, N. C., Hulshof, T. A. & Koolman, X. Terminal illness and the increased mortality risk of conventional antipsychotics in observational studies: a systematic review. Pharmacoepidemiol Drug Saf \n                           25, 113\u2013122, doi:10.1002\/pds.3912 (2016).","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"11323_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/0253-7176.119471","volume":"35","author":"N Malhotra","year":"2013","unstructured":"Malhotra, N., Grover, S., Chakrabarti, S. & Kulhara, P. Metabolic syndrome in schizophrenia. Indian J Psychol Med \n                           35, 227\u2013240, doi:10.4103\/0253-7176.119471 (2013).","journal-title":"Indian J Psychol Med"},{"key":"11323_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.4088\/JCP.v68n0612","volume":"68","author":"TM Laursen","year":"2007","unstructured":"Laursen, T. M., Munk-Olsen, T., Nordentoft, M. & Mortensen, P. B. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry \n                           68, 899\u2013907 (2007).","journal-title":"J Clin Psychiatry"},{"key":"11323_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4103\/0253-7613.140579","volume":"46","author":"BK Choure","year":"2014","unstructured":"Choure, B. K., Gosavi, D. & Nanotkar, S. Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study. Indian J Pharmacol \n                           46, 493\u2013497, doi:10.4103\/0253-7613.140579 (2014).","journal-title":"Indian J Pharmacol"},{"key":"11323_CR12","first-page":"877","volume":"55","author":"LA Nussbaum","year":"2014","unstructured":"Nussbaum, L. A. et al. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Rom J Morphol Embryol \n                           55, 877\u2013884 (2014).","journal-title":"Rom J Morphol Embryol"},{"key":"11323_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2217\/pgs.11.40","volume":"12","author":"JG Gregoor","year":"2011","unstructured":"Gregoor, J. G. et al. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics \n                           12, 919\u2013923, doi:10.2217\/pgs.11.40 (2011).","journal-title":"Pharmacogenomics"},{"key":"11323_CR14","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1073\/pnas.0611417104","volume":"104","author":"SF Kim","year":"2007","unstructured":"Kim, S. F., Huang, A. S., Snowman, A. M., Teuscher, C. & Snyder, S. H. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA \n                           104, 3456\u20133459, doi:10.1073\/pnas.0611417104 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"11323_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","volume":"100","author":"H Jin","year":"2008","unstructured":"Jin, H., Meyer, J. M., Mudaliar, S. & Jeste, D. V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res \n                           100, 70\u201385, doi:10.1016\/j.schres.2007.11.026 (2008).","journal-title":"Schizophr Res"},{"key":"11323_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","volume":"450","author":"AK Sarvari","year":"2014","unstructured":"Sarvari, A. K., Vereb, Z., Uray, I. P., Fesus, L. & Balajthy, Z. Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes. In vitro. Biochem Biophys Res Commun \n                           450, 1383\u20131389, doi:10.1016\/j.bbrc.2014.07.005 (2014).","journal-title":"In vitro. Biochem Biophys Res Commun"},{"key":"11323_CR17","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.pnpbp.2011.07.017","volume":"35","author":"AL Sertie","year":"2011","unstructured":"Sertie, A. L. et al. Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism. Prog Neuropsychopharmacol Biol Psychiatry \n                           35, 1884\u20131890, doi:10.1016\/j.pnpbp.2011.07.017 (2011).","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"11323_CR18","doi-asserted-by":"publisher","unstructured":"Ye, J. & DeBose-Boyd, R. A. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol \n                           3, doi:10.1101\/cshperspect.a004754 (2011).","DOI":"10.1101\/cshperspect.a004754"},{"key":"11323_CR19","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1101\/gad.1854309","volume":"23","author":"TF Osborne","year":"2009","unstructured":"Osborne, T. F. & Espenshade, P. J. Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it\u2019s been. Genes Dev \n                           23, 2578\u20132591, doi:10.1101\/gad.1854309 (2009).","journal-title":"Genes Dev"},{"key":"11323_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest \n                           109, 1125\u20131131, doi:10.1172\/JCI15593 (2002).","journal-title":"J Clin Invest"},{"key":"11323_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.cell.2011.09.045","volume":"147","author":"AK Walker","year":"2011","unstructured":"Walker, A. K. et al. A conserved SREBP-1\/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell \n                           147, 840\u2013852, doi:10.1016\/j.cell.2011.09.045 (2011).","journal-title":"Cell"},{"key":"11323_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.mp.4002133","volume":"14","author":"S Le Hellard","year":"2009","unstructured":"Le Hellard, S. et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry \n                           14, 308\u2013317, doi:10.1038\/sj.mp.4002133 (2009).","journal-title":"Mol Psychiatry"},{"key":"11323_CR23","doi-asserted-by":"publisher","first-page":"12753","DOI":"10.1073\/pnas.162488899","volume":"99","author":"D Yabe","year":"2002","unstructured":"Yabe, D., Brown, M. S. & Goldstein, J. L. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA \n                           99, 12753\u201312758, doi:10.1073\/pnas.162488899 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"11323_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/tpj.2010.74","volume":"12","author":"YJ Liou","year":"2012","unstructured":"Liou, Y. J. et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J \n                           12, 54\u201361, doi:10.1038\/tpj.2010.74 (2012).","journal-title":"Pharmacogenomics J"},{"key":"11323_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.161","volume":"5","author":"HL Cai","year":"2015","unstructured":"Cai, H. L. et al. A potential mechanism underlying atypical antipsychotics-induced lipid disturbances. Transl Psychiatry \n                           5, e661, doi:10.1038\/tp.2015.161 (2015).","journal-title":"Transl Psychiatry"},{"key":"11323_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.tpj.6500323","volume":"5","author":"J Ferno","year":"2005","unstructured":"Ferno, J. et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J \n                           5, 298\u2013304, doi:10.1038\/sj.tpj.6500323 (2005).","journal-title":"Pharmacogenomics J"},{"key":"11323_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00210-010-0499-4","volume":"381","author":"E Lauressergues","year":"2010","unstructured":"Lauressergues, E. et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol \n                           381, 427\u2013439, doi:10.1007\/s00210-010-0499-4 (2010).","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"11323_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-010-0597-3","volume":"383","author":"E Lauressergues","year":"2011","unstructured":"Lauressergues, E. et al. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn Schmiedebergs Arch Pharmacol \n                           383, 423\u2013436, doi:10.1007\/s00210-010-0597-3 (2011).","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"11323_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/pgs.13.157","volume":"15","author":"TJ Vassas","year":"2014","unstructured":"Vassas, T. J., Burghardt, K. J. & Ellingrod, V. L. Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics \n                           15, 61\u201367, doi:10.2217\/pgs.13.157 (2014).","journal-title":"Pharmacogenomics"},{"key":"11323_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2741\/3675","volume":"16","author":"J Ferno","year":"2011","unstructured":"Ferno, J. et al. Lipogenic effects of psychotropic drugs: focus on the SREBP system. Front Biosci (Landmark Ed) \n                           16, 49\u201360 (2011).","journal-title":"Front Biosci (Landmark Ed)"},{"key":"11323_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","volume":"203","author":"J Ferno","year":"2009","unstructured":"Ferno, J. et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) \n                           203, 73\u201384, doi:10.1007\/s00213-008-1370-x (2009).","journal-title":"Psychopharmacology (Berl)"},{"key":"11323_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11010-006-9160-4","volume":"289","author":"MB Raeder","year":"2006","unstructured":"Raeder, M. B., Ferno, J., Vik-Mo, A. O. & Steen, V. M. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem \n                           289, 167\u2013173, doi:10.1007\/s11010-006-9160-4 (2006).","journal-title":"Mol Cell Biochem"},{"key":"11323_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.phrs.2007.05.007","volume":"56","author":"LH Yang","year":"2007","unstructured":"Yang, L. H., Chen, T. M., Yu, S. T. & Chen, Y. H. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res \n                           56, 202\u2013208, doi:10.1016\/j.phrs.2007.05.007 (2007).","journal-title":"Pharmacol Res"},{"key":"11323_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14740338.2016.1201475","volume":"15","author":"L Orsolini","year":"2016","unstructured":"Orsolini, L. et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf \n                           15, 1329\u20131347, doi:10.1080\/14740338.2016.1201475 (2016).","journal-title":"Expert Opin Drug Saf"},{"key":"11323_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1055\/s-2007-979318","volume":"31","author":"K Broich","year":"1998","unstructured":"Broich, K., Heinrich, S. & Marneros, A. Acute clozapine overdose: plasma concentration and outcome. Pharmacopsychiatry \n                           31, 149\u2013151, doi:10.1055\/s-2007-979318 (1998).","journal-title":"Pharmacopsychiatry"},{"key":"11323_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-2004-815527","volume":"37","author":"N Bergemann","year":"2004","unstructured":"Bergemann, N., Frick, A., Parzer, P. & Kopitz, J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry \n                           37, 63\u201368, doi:10.1055\/s-2004-815527 (2004).","journal-title":"Pharmacopsychiatry"},{"key":"11323_CR37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0269881107077357","volume":"21","author":"L Wang","year":"2007","unstructured":"Wang, L. et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol \n                           21, 837\u2013842, doi:10.1177\/0269881107077357 (2007).","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"11323_CR38","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer, J. W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs \n                           19(Suppl 1), 1\u201393 (2005).","journal-title":"CNS Drugs"},{"key":"11323_CR39","doi-asserted-by":"publisher","first-page":"856","DOI":"10.4088\/JCP.v63n1002","volume":"63","author":"DA Wirshing","year":"2002","unstructured":"Wirshing, D. A. et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry \n                           63, 856\u2013865 (2002).","journal-title":"J Clin Psychiatry"},{"key":"11323_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0920-9964(02)00158-5","volume":"59","author":"SP Baymiller","year":"2003","unstructured":"Baymiller, S. P., Ball, P., McMahon, R. P. & Buchanan, R. W. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res \n                           59, 49\u201357 (2003).","journal-title":"Schizophr Res"},{"key":"11323_CR41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1600-065X.2012.01151.x","volume":"249","author":"AR Johnson","year":"2012","unstructured":"Johnson, A. R., Milner, J. J. & Makowski, L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev \n                           249, 218\u2013238, doi:10.1111\/j.1600-065X.2012.01151.x (2012).","journal-title":"Immunol Rev"},{"key":"11323_CR42","doi-asserted-by":"publisher","first-page":"E1178","DOI":"10.1152\/ajpendo.00002.2004","volume":"287","author":"AH Berg","year":"2004","unstructured":"Berg, A. H., Lin, Y., Lisanti, M. P. & Scherer, P. E. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab \n                           287, E1178\u20131188, doi:10.1152\/ajpendo.00002.2004 (2004).","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"11323_CR43","doi-asserted-by":"publisher","unstructured":"Moseti, D., Regassa, A. & Kim, W. K. Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules. Int J Mol Sci \n                           17, doi:10.3390\/ijms17010124 (2016).","DOI":"10.3390\/ijms17010124"},{"key":"11323_CR44","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1073\/pnas.0400356101","volume":"101","author":"T Imai","year":"2004","unstructured":"Imai, T. et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA \n                           101, 4543\u20134547, doi:10.1073\/pnas.0400356101 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"11323_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","volume":"77","author":"P Tontonoz","year":"2008","unstructured":"Tontonoz, P. & Spiegelman, B. M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem \n                           77, 289\u2013312, doi:10.1146\/annurev.biochem.77.061307.091829 (2008).","journal-title":"Annu Rev Biochem"},{"key":"11323_CR46","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison, D. B. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry \n                           156, 1686\u20131696 (1999).","journal-title":"Am J Psychiatry"},{"key":"11323_CR47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ygeno.2005.07.010","volume":"86","author":"AC Cervino","year":"2005","unstructured":"Cervino, A. C. et al. Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics \n                           86, 505\u2013517, doi:10.1016\/j.ygeno.2005.07.010 (2005).","journal-title":"Genomics"},{"key":"11323_CR48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1126\/science.1124779","volume":"312","author":"A Herbert","year":"2006","unstructured":"Herbert, A. et al. A common genetic variant is associated with adult and childhood obesity. Science \n                           312, 279\u2013283, doi:10.1126\/science.1124779 (2006).","journal-title":"Science"},{"key":"11323_CR49","doi-asserted-by":"publisher","first-page":"10099","DOI":"10.1074\/jbc.M111.303669","volume":"287","author":"L Plantier","year":"2012","unstructured":"Plantier, L. et al. Activation of sterol-response element-binding proteins (SREBP) in alveolar type II cells enhances lipogenesis causing pulmonary lipotoxicity. J Biol Chem \n                           287, 10099\u201310114, doi:10.1074\/jbc.M111.303669 (2012).","journal-title":"J Biol Chem"},{"key":"11323_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.euroneuro.2015.04.028","volume":"25","author":"R Dang","year":"2015","unstructured":"Dang, R. et al. Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG\/SREBP pathway. Eur Neuropsychopharmacol \n                           25, 1239\u20131247, doi:10.1016\/j.euroneuro.2015.04.028 (2015).","journal-title":"Eur Neuropsychopharmacol"},{"key":"11323_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1210\/me.2004-0324","volume":"19","author":"S Lee","year":"2005","unstructured":"Lee, S., Lee, D. K., Choi, E. & Lee, J. W. Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes. Mol Endocrinol \n                           19, 399\u2013408, doi:10.1210\/me.2004-0324 (2005).","journal-title":"Mol Endocrinol"},{"key":"11323_CR52","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1002\/jcp.24042","volume":"227","author":"LW Hsu","year":"2012","unstructured":"Hsu, L. W. et al. The effect of exogenous histone H1 on rat adipose-derived stem cell proliferation, migration, and osteogenic differentiation in vitro. J Cell Physiol \n                           227, 3417\u20133425, doi:10.1002\/jcp.24042 (2012).","journal-title":"J Cell Physiol"},{"key":"11323_CR53","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.biopha.2016.10.066","volume":"84","author":"CC Chen","year":"2016","unstructured":"Chen, C. C. et al. DHL-HisZn, a novel antioxidant, enhances adipogenic differentiation and antioxidative response in adipose-derived stem cells. Biomed Pharmacother \n                           84, 1601\u20131609, doi:10.1016\/j.biopha.2016.10.066 (2016).","journal-title":"Biomed Pharmacother"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11323-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:35:07Z","timestamp":1671791707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11323-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,7]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11323"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-11323-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,7]]},"assertion":[{"value":"3 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10901"}}